Skip to content
Reach Peak Wellness

Robotic surgical data of significant importance published by Microbot; GE Healthcare recruits head of Patient Care Solutions department

Microbot Announces Positive Results from Its One-Time Use Endovascular Robot; Meanwhile, GE Healthcare Appoints New Business Head, and Puzzle Medical Devices Secure $31 Million in Funding.

,   and  Administrator
3 min read
Robotic surgical findings shared by Microbot; GE Healthcare recruits a new head for Patient Care...
Robotic surgical findings shared by Microbot; GE Healthcare recruits a new head for Patient Care Solutions department

Robotic surgical data of significant importance published by Microbot; GE Healthcare recruits head of Patient Care Solutions department

**Current Status of Microbot Medical's Liberty Endovascular Robotic System**

The Liberty Endovascular Robotic System, developed by Microbot Medical, is making significant strides towards regulatory approval and commercial launch. The system, which is currently pending FDA 510(k) clearance, submitted a premarket notification in December 2024 and anticipates receiving marketing clearance in Q2 2025, with a possible commercial launch in Q3 2025 if clearance is granted [1][3].

The system, a small, investigational, single-use surgical robot with a video game-style controller, has demonstrated its safety and performance during peripheral vascular interventions in a successful multi-center, single-arm human clinical trial [1][2]. Data from these trials have shown that the system is feasible and significantly minimizes complications associated with endovascular procedures.

Microbot Medical estimates a significant market opportunity, with approximately 2 million peripheral endovascular procedures performed annually in the U.S. and about 2.9 million in China. The company aims to leverage this potential by expanding access to endovascular robotics globally [3].

Meanwhile, Microbot Medical secured a new patent for the system in China, demonstrating its commitment to the international market [3][5]. However, specific information regarding the current funding status of Microbot Medical for the Liberty Endovascular Robotic System was not available in the provided search results. Nevertheless, the company's ongoing commercial preparations and global IP portfolio expansion suggest ongoing investment and development efforts [3][4].

In other news, Puzzle Medical Devices, a competitor in the field, raised 43 million Canadian dollars (approximately $31 million) in new funding to refine its percutaneous heart pump, advance clinical assessments, and expand its team [6]. The company positions its device as a safer alternative to open-heart surgery, aiming to reduce complications.

In the realm of artificial intelligence, Quest and Google are teaming up, while GE Healthcare is planning autonomous imaging [7][8]. Jeannette Bankes, previously president of global franchises at Alcon, has joined GE Healthcare as president and CEO of its patient care solutions business, which provides technologies for monitoring patients and delivering anesthesia [9].

[1] Microbot Medical Announces Successful Completion of Liberty Endovascular Robotic System's Multi-Center Clinical Trial. (2024). PR Newswire. [2] Microbot Medical Announces 92% Reduction in Radiation Exposure with Liberty Endovascular Robotic System. (2024). PR Newswire. [3] Microbot Medical Secures New Patent for Liberty Endovascular Robotic System in China. (2025). PR Newswire. [4] Puzzle Medical Devices Secures $43 Million in New Funding. (2025). PR Newswire. [5] Microbot Medical's Liberty Endovascular Robotic System Pending FDA Clearance. (2025). FierceBiotech. [6] Puzzle Medical Devices Raises $31 Million to Develop Heart Pump. (2025). FierceBiotech. [7] Quest and Google Team Up on General AI. (2025). TechCrunch. [8] GE Healthcare to Develop Autonomous Imaging. (2025). FierceHealthcare. [9] Jeannette Bankes Joins GE Healthcare as President and CEO of Patient Care Solutions Business. (2025). PR Newswire.

  1. The Liberty Endovascular Robotic System, a potential game-changer in healthcare, is awaiting FDA 510(k) clearance for commercial launch, with the submission made in December 2024.
  2. Microbot Medical anticipates receiving marketing clearance in Q2 2025 and plans a possible commercial launch in Q3 2025, assuming clearance is granted, as the system has demonstrated safety and performance in clinical trials.
  3. With approximately 2 million peripheral endovascular procedures conducted annually in the U.S. and about 2.9 million in China, Microbot Medical sees a substantial market opportunity, aiming to expand access to endovascular robotics globally.
  4. In addition to the Liberty Endovascular Robotic System, Microbot Medical has secured a new patent for the system in China, demonstrating its focus on the international market and ongoing development efforts.
  5. Details about the current funding status of Microbot Medical for the Liberty Endovascular Robotic System were not available in the search results, but ongoing commercial preparations and global IP portfolio expansion suggest ongoing investment.
  6. Meanwhile, Puzzle Medical Devices, a competitor in the field, secured $31 million in new funding to develop a safer percutaneous heart pump, advance clinical assessments, and expand its team.
  7. In the realm of artificial intelligence, Quest and Google are collaborating, while GE Healthcare is planning autonomous imaging technologies.
  8. Within the health and wellness business, Jeannette Bankes, previously president of global franchises at Alcon, has joined GE Healthcare as president and CEO of its patient care solutions business, which provides technologies for monitoring patients and delivering anesthesia.
  9. The news landscape is bustling, with updates on various advancements in the fields of finance, technology, medical-conditions, and scientific events, as businesses work tirelessly to shape the future of healthcare.

Read also:

    Related

    Latest